The following is a summary of the Tandem Diabetes Care, Inc. (TNDM) Q3 2024 Earnings Conference Call Transcript:

Financial Performance:

• Tandem Diabetes Care reported record quarterly sales of $243 million in Q3 2024, marking the highest worldwide sales in company history.

• Gross margin for Q3 stood at 51%, in line with expectations despite pressures related to the Mobi launch.

• Adjusted EBITDA turned positive at 2% of sales in Q3 highlighting a return to profitability.

• Positive free cash flow generation of $22 million was achieved in Q3.

Business Progress:

• There was noteworthy year-over-year new pump growth in the United States, particularly from MDI users, indicating successful market expansion efforts.

• Tandem Diabetes achieved notable milestones in its operational performance and returned to positive free cash flow in Q3.

• The introduction of Tandem Mobi and ongoing enthusiasm for t:slim X2 have driven strong customer feedback and pump sales.

• Regulatory win in the European Union with the clearance of T:slim X2 for use with Lyumjev, expanding product usability.

Opportunities:

• Continued growth and expansion in the international markets with a record number of pump placements and high customer retention.

• New tenders starting from 2025 which will enhance customer access in select countries.

• Broadening product acceptance and increased market penetration through strategic plans like integration of Abbott's FreeStyle Libre 3.

• The launch of new products like Tandem Mobi is expected to be key in driving margin expansion and market growth.

Risks:

• The roll-out and scaling of the new Mobi platform, which is expected to initially place pressure on gross margins.

• Regulatory and market acceptance risks associated with new product releases and market expansions.

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.